More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The Administration for Strategic Preparedness and Response is seeking public feedback on its Hospital Preparedness Program funding formula. The HPP is the…
Headline
In this AHA blog Aisha Syeda, senior program manager for AHA’s Strategic Initiatives, summarizes five action steps hospitals can take to establish pediatric…
Blog
In 2024, the U.S. suffered 24 weather and climate disasters. In October alone, two major hurricanes devastated communities in North Carolina and Florida,…
Headline
Reports of cases of pertussis, also known as whooping cough, are currently five times higher compared to last year, according to the Centers for Disease…
Headline
The Centers for Disease Control and Prevention Oct. 25 announced additional reported cases of E. coli from individuals who ate at McDonald's prior to falling…
Headline
The Centers for Disease Control and Prevention has issued a health advisory on the supply disruption of peritoneal dialysis and intravenous solutions due to…